Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463]
| Autor: | Oh, D., He, A.R., Qin, S., Chen, L., Okusaka, T., Vogel, A., Kim, J.W., Suksombooncharoen, T., Lee, M.A., Kitano, M., Burris, H.A., Bouattour, M., Tanasa, S., Zaucha, R.E., Avallone, A., Cundom, J.E., Rokutanda, N., Żotkiewicz, M., Cohen, G., Valle, J.W. |
|---|---|
| Zdroj: | In Annals of Oncology July 2023 34(7):633-633 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|